Sjogren's Syndrome Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight

DelveInsight's, "Sjogren's syndrome Pipeline Insight, 2026" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Sjogren's syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Learn more about our innovative pipeline today! @ Sjogren's Syndrome Pipeline Outlook- https://www.delveinsight.com/sample-request/sjogrens-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Key Takeaways from the Sjogren's Syndrome Pipeline Report
• In August 2026, Vor Bio reported that enrollment was progressing as planned in the Phase III clinical trial of telitacicept for primary Sjögren's disease, with topline results expected in the first half of 2027.
• In May 2026, InnoCare Pharma announced approval to initiate a Phase II clinical trial of its TYK2 inhibitor ICP-488 for the treatment of Sjögren's syndrome in China.
• In June, 2026- Vor Biopharma initiated a Phase 3 Study to Evaluate the Efficacy and Safety of Telitacicept in Adult Participants With Active Primary Sjögren's Disease. Telitacicept (RC18) is a recombinant fusion protein designed to target B-cell-mediated immune pathways. It consists of the extracellular domain of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) linked to the Fc portion of human immunoglobulin G1 (IgG1).
• In June, 2026- Novartis Pharmaceuticals conducted a phase 3 study of the clinical efficacy, safety and tolerability of ianalumab (VAY736) in patients with active Sjogren's syndrome. The purpose of this study is to demonstrate the clinical efficacy, safety and tolerability of ianalumab (VAY736) administered subcutaneously (s.c.) monthly or every 3 months compared to placebo in patients with active Sjogren's syndrome.
• DelveInsight's Sjogren's Syndrome pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Sjogren's Syndrome treatment.
• The leading Sjogren's Syndrome Companies such as Novartis, Horizon Therapeutics, Bristol-Myers Squibb, Rise Therapeutics, Resolve Therapeutics, Dompé Farmaceutici, Amgen, Rise Therapeutics and others.
• Promising Sjogren's Syndrome Pipeline Therapies such as Baricitinib, Hydroxychloroquine, HZN-1116, Nipocalimab, RSLV-132, Lanraplenib, Filgotinib, Tirabrutinib, RO5459072 and others.

Download for updates and be a part of the revolution in Immunological and Autoimmune Disorders Care @ https://www.delveinsight.com/sample-request/sjogrens-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Sjogren's syndrome Overview
Sjogren's syndrome (SS) is a chronic autoimmune disease with a specific predisposition for causing inflammation of the exocrine glands, predominantly the salivary and lacrimal glands, including the nose, upper respiratory tract, oropharynx, and, in women, the vagina. In SS, the immune system inappropriately attacks various cells, leading to activation of the various pathways, and resulting in inflammation. The main consequence of this inflammation is the development of sicca symptoms due to damage to the salivary and tear glands, such as dryness of the mucosal surfaces, principally in the mouth and eyes. If cytokines, chemokines and autoantibodies are expressed by the epithelium of the exocrine glands: Increased levels of cytokines, chemokine, and autoantibodies expressed by the epithelium of the exocrine glands (such as the salivary and lacrimal glands) lead to chronic inflammation and the eventual loss of their physiological functions.

Sjogren's Syndrome Emerging Drugs Profile

• VAY736: Novartis
VAY736 (ianalumab) is a novel, intravenous, defucosylated, human IgG1/κ monoclonal antibody that targets the human B cell-activating factor (BAFF) of the TNF family. The BAFF receptor is predominantly expressed on B cells and is critically involved in B cell maturation, activation, and survival. VAY736 targets the BAFF receptor and competitively inhibits BAFF binding to BAFF-R, thereby blocking BAFF-R-mediated signaling in B cells. It is also engineered to effectively eliminate B cells from circulation in vivo by antibody-dependent cellular cytotoxicity (ADCC). The ADCC activity of ianalumab is greatly enhanced by eliminating fucose residues from the carbohydrate moiety attached to the Fc part of the antibody. The molecule is being developed by Novartis in partnership with MorphoSys as an antibody-based therapy. The drug is currently in Phase III clinical studies for the treatment of Sjögren's Syndrome (SS).

• Dazodalibep: Amgen
Dazodalibep (VIB4920) is a fusion protein developed by Horizon therapeutics, designed to bind to CD40L on activated T-cells, blocking their interaction with CD40-expressing B-cells. According to the company, this approach could inhibit the stimulation of dendritic cells and monocytes, thereby reducing the production of molecules that cause inflammation endemic to T- and B-cell-driven diseases. Currently, the drug is in the Phase III stage of its development for the treatment of Sjögren's Syndrome.

• R-2487: Rise Therapeutics
R-2487 is a targeted oral immune therapy that has the ability to induce T regulatory cell populations. R-2487 has a unique mechanism of action by which it can engage specific immune pathways that regulate tolerance and reset T regulatory deficiencies to reduce specific inflammatory cytokines that contribute to autoimmune disease. This mechanism is particularly important in the context of treating autoimmune disease. The drug is currently in Phase I clinical studies for the treatment of Sjögren's Syndrome.

The Sjogren's Syndrome Pipeline Report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Sjogren's Syndrome with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sjogren's Syndrome Treatment.
• Sjogren's Syndrome Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Sjogren's Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sjogren's Syndrome market.

Learn more about Sjogren's Syndrome Drugs opportunities in our groundbreaking Sjogren's Syndrome research and development projects @ https://www.delveinsight.com/sample-request/sjogrens-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Sjogren's Syndrome Companies
Novartis, Horizon Therapeutics, Bristol-Myers Squibb, Rise Therapeutics, Resolve Therapeutics, Dompé Farmaceutici, Amgen, Rise Therapeutics and others.

Sjogren's syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Sjogren's Syndrome Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Stay informed about how we're transforming the future of Immunological and Autoimmune Disorders @ https://www.delveinsight.com/sample-request/sjogrens-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Scope of the Sjogren's Syndrome Pipeline Report
• Coverage- Global
• Sjogren's Syndrome Companies- Novartis, Horizon Therapeutics, Bristol-Myers Squibb, Rise Therapeutics, Resolve Therapeutics, Dompé Farmaceutici, Amgen, Rise Therapeutics and others.
• Sjogren's Syndrome Pipeline Therapies- Baricitinib, Hydroxychloroquine, HZN-1116, Nipocalimab, RSLV-132, Lanraplenib, Filgotinib, Tirabrutinib, RO5459072 and others.
• Sjogren's Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Sjogren's Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Read the full details of Sjogren's Syndrome Pipeline on our website @ https://www.delveinsight.com/sample-request/sjogrens-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Table of contents
1. Introduction
2. Executive Summary
3. Sjogren's syndrome: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Sjogren's syndrome- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. VAY736: Novartis
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. Product Name: Company Name
12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I)
14. Product Name: Company Name
15. Drug profiles in the detailed report.....
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report.....
19. Inactive Products
20. Sjogren's syndrome Key Companies
21. Sjogren's syndrome Key Products
22. Sjogren's syndrome- Unmet Needs
23. Sjogren's syndrome- Market Drivers and Barriers
24. Sjogren's syndrome- Future Perspectives and Conclusion
25. Sjogren's syndrome Analyst Views
26. Sjogren's syndrome Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com

This release was published on openPR.